x | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | 27-2004382 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
11055 Flintkote Avenue, San Diego, California | 92121 | |
(Address of principal executive offices) | (Zip Code) | |
(858) 952-7570 | ||
(Registrant’s telephone number, including area code) |
Large accelerated filer | o | Accelerated filer | o | ||||
Non-accelerated filer | o | (Do not check if a smaller reporting company) | Smaller reporting company | x | |||
Emerging growth company | o | ||||||
Page | ||
September 30, 2018 | December 31, 2017 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 15,065,913 | $ | 8,225,764 | |||
Accounts receivable and unbilled receivable | 128,577 | 77,095 | |||||
Prepaid expenses and other current assets | 849,082 | 1,165,828 | |||||
Total current assets | 16,043,572 | 9,468,687 | |||||
Property and equipment, net | 1,627,605 | 2,426,312 | |||||
Other assets | 249,645 | 389,942 | |||||
Total Assets | $ | 17,920,822 | $ | 12,284,941 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 476,300 | $ | 825,244 | |||
Accrued expenses | 1,718,060 | 1,454,587 | |||||
Deferred rent, current portion | 472,251 | 334,424 | |||||
Current portion of long-term debt | — | 1,331,515 | |||||
Total current liabilities | 2,666,611 | 3,945,770 | |||||
Derivative financial instruments—warrants | 70,347 | 649,387 | |||||
Deferred rent, net of current portion | 1,204,109 | 1,183,677 | |||||
Total Liabilities | 3,941,067 | 5,778,834 | |||||
Commitments and contingencies (Note 8) | |||||||
Stockholders’ equity | |||||||
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 277,100 designated as Series A Convertible Preferred Stock; 60,600 shares outstanding at September 30, 2018 and December 31, 2017 with liquidation preference of $606,000 at September 30, 2018 and December 31, 2017; 8,860 designated as Series B Convertible Preferred Stock; 0 shares outstanding at September 30, 2018 and December 31, 2017, respectively | 60 | 60 | |||||
Common stock, $0.0001 par value, 150,000,000 shares authorized; 22,957,192 and 4,399,299 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | 7,738 | 5,279 | |||||
Additional paid-in capital | 201,998,634 | 179,546,954 | |||||
Accumulated deficit | (188,026,677 | ) | (173,046,186 | ) | |||
Total stockholders’ equity | 13,979,755 | 6,506,107 | |||||
Total liabilities and stockholders’ equity | $ | 17,920,822 | $ | 12,284,941 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||
Revenues: | |||||||||||||||
Royalties | $ | 72,568 | $ | 58,779 | $ | 174,046 | $ | 169,415 | |||||||
Diagnostic services | 4,303 | 58,119 | 83,650 | 142,482 | |||||||||||
Clinical research services | 11,490 | 6,431 | 42,614 | 8,481 | |||||||||||
Total revenues | 88,361 | 123,329 | 300,310 | 320,378 | |||||||||||
Costs and expenses: | |||||||||||||||
Cost of revenues | 26,677 | 473,202 | 597,457 | 1,427,831 | |||||||||||
Research and development | 1,830,441 | 1,414,706 | 5,667,046 | 6,676,251 | |||||||||||
Selling, general and administrative | 1,665,200 | 4,079,514 | 6,321,048 | 12,358,290 | |||||||||||
Restructuring charges (benefit) | 421,351 | (46,472 | ) | 664,686 | 1,669,526 | ||||||||||
Total operating expenses | 3,943,669 | 5,920,950 | 13,250,237 | 22,131,898 | |||||||||||
Loss from operations | (3,855,308 | ) | (5,797,621 | ) | (12,949,927 | ) | (21,811,520 | ) | |||||||
Interest income | 85,938 | 20,650 | 143,911 | 132,515 | |||||||||||
Interest expense | (16 | ) | (37,123 | ) | (25,177 | ) | (1,010,256 | ) | |||||||
(Loss) gain from change in fair value of derivative financial instruments—warrants | (2,500 | ) | 1,528,669 | 579,040 | 2,012,747 | ||||||||||
Gain (loss) on extinguishment of debt | — | — | 17,974 | (1,655,825 | ) | ||||||||||
Other income (loss), net | 2,318 | (6,541 | ) | (68,521 | ) | (4,975 | ) | ||||||||
Net loss | (3,769,568 | ) | (4,291,966 | ) | (12,302,700 | ) | (22,337,314 | ) | |||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock | (6,060 | ) | (6,060 | ) | (18,180 | ) | (18,180 | ) | |||||||
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance | — | — | (2,769,533 | ) | — | ||||||||||
Net loss attributable to common stockholders | $ | (3,775,628 | ) | $ | (4,298,026 | ) | $ | (15,090,413 | ) | $ | (22,355,494 | ) | |||
Net loss per common share — basic | $ | (0.18 | ) | $ | (1.41 | ) | $ | (1.38 | ) | $ | (8.17 | ) | |||
Net loss per common share — diluted | $ | (0.18 | ) | $ | (1.41 | ) | $ | (1.38 | ) | $ | (8.17 | ) | |||
Weighted-average shares outstanding — basic | 20,622,660 | 3,038,806 | 10,945,249 | 2,735,526 | |||||||||||
Weighted-average shares outstanding — diluted | 20,622,660 | 3,038,806 | 10,945,249 | 2,735,526 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||
Net loss | $ | (3,769,568 | ) | $ | (4,291,966 | ) | $ | (12,302,700 | ) | $ | (22,337,314 | ) | |||
Other comprehensive income (loss): | |||||||||||||||
Foreign currency translation loss | — | (1,544 | ) | — | (13,486 | ) | |||||||||
Unrealized gain or reversal of previous losses on securities available-for-sale | — | — | — | 9,065 | |||||||||||
Total other comprehensive loss | — | (1,544 | ) | — | (4,421 | ) | |||||||||
Total comprehensive loss | (3,769,568 | ) | (4,293,510 | ) | (12,302,700 | ) | (22,341,735 | ) | |||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock | (6,060 | ) | (6,060 | ) | (18,180 | ) | (18,180 | ) | |||||||
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance | — | — | (2,769,533 | ) | — | ||||||||||
Comprehensive loss attributable to common stockholders | $ | (3,775,628 | ) | $ | (4,299,570 | ) | $ | (15,090,413 | ) | $ | (22,359,915 | ) |
Preferred Stock Shares | Preferred Stock Amount | Common Stock Shares | Common Stock Amount | Additional Paid-In Capital | Accumulated Deficit | Total Stockholders’ Equity | |||||||||||||||||||
Balance, January 1, 2018 | 60,600 | $ | 60 | 4,399,299 | $ | 5,279 | $ | 179,546,954 | $ | (173,046,186 | ) | $ | 6,506,107 | ||||||||||||
Stock-based compensation | — | — | — | — | 1,905,652 | — | 1,905,652 | ||||||||||||||||||
Sale of common stock and warrants, net of expenses | — | — | 9,140,000 | 914 | 11,778,611 | — | 11,779,525 | ||||||||||||||||||
Sale of Series B Convertible Preferred Stock, net of expenses | 8,860 | 9 | — | — | 4,386,753 | — | 4,386,762 | ||||||||||||||||||
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance | — | — | — | — | 2,769,533 | (2,769,533 | ) | — | |||||||||||||||||
Issuance of common stock upon exercise of warrants | — | — | 473,497 | 569 | 1,612,098 | — | 1,612,667 | ||||||||||||||||||
Issuance of common stock upon vesting of restricted stock units | — | — | 77,572 | 90 | (90 | ) | — | — | |||||||||||||||||
Issuance of common stock upon conversion of Series B Convertible Preferred Stock | (8,860 | ) | (9 | ) | 8,860,000 | 886 | (877 | ) | — | — | |||||||||||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock | — | — | — | — | — | (18,180 | ) | (18,180 | ) | ||||||||||||||||
Issuance of common stock for share rounding as a result of reverse stock split | — | — | 6,824 | — | — | — | — | ||||||||||||||||||
Cumulative adjustment upon adoption of ASC 606 | — | — | — | — | — | 109,922 | 109,922 | ||||||||||||||||||
Net loss | — | — | — | — | — | (12,302,700 | ) | (12,302,700 | ) | ||||||||||||||||
Balance, September 30, 2018 | 60,600 | $ | 60 | 22,957,192 | $ | 7,738 | $ | 201,998,634 | $ | (188,026,677 | ) | $ | 13,979,755 |
Nine Months Ended September 30, | |||||||
2018 | 2017 | ||||||
Operating activities | |||||||
Net loss | $ | (12,302,700 | ) | $ | (22,337,314 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Loss on disposal of assets | 197,490 | 28,199 | |||||
Impairment loss | 187,500 | 485,000 | |||||
Depreciation and amortization | 701,774 | 956,995 | |||||
Stock based compensation expense | 1,905,652 | 3,117,364 | |||||
(Gain) loss on extinguishment of debt | (17,974 | ) | 1,655,825 | ||||
Accretion of final fee premium | — | 293,614 | |||||
Amortization of discount on debt | — | 113,780 | |||||
Net realized loss on short-term investments | — | 6,400 | |||||
Amortization of premiums on short-term investments | — | 9,230 | |||||
Deferred rent | (266,556 | ) | (207,435 | ) | |||
Interest income accrued on short-term investments | — | (90,330 | ) | ||||
Change in fair value of derivative financial instruments—warrants | (579,040 | ) | (2,012,747 | ) | |||
Changes in operating assets and liabilities: | |||||||
Increase in other assets | (170,602 | ) | — | ||||
Decrease (increase) in accounts receivable and unbilled receivable | 58,440 | (77,667 | ) | ||||
Decrease in prepaid expenses and other current assets | 316,746 | 18,230 | |||||
Increase (decrease) in accounts payable and accrued expenses | 383,037 | (1,908,796 | ) | ||||
Net cash used in operating activities | (9,586,233 | ) | (19,949,652 | ) | |||
Investing activities: | |||||||
Proceeds from disposals of capital equipment | 27,942 | — | |||||
Capital expenditures | (5,100 | ) | (136,251 | ) | |||
Maturities of short-term investments | — | 16,431,837 | |||||
Purchases of short-term investments | (31,500 | ) | (8,804,604 | ) | |||
Sales of short-term investments | 31,500 | 16,434,553 | |||||
Net cash provided by investing activities | 22,842 | 23,925,535 | |||||
Financing activities: | |||||||
Proceeds from sales of common stock and warrants, net of expenses of $1,336,123 and $575,516, respectively | 11,779,525 | 6,634,803 | |||||
Proceeds from sales of Series B Convertible Preferred Stock, net of expenses of $497,617 | 4,386,762 | — | |||||
Proceeds from exercise of warrants | 1,612,667 | — | |||||
Payment upon debt extinguishment | (175,381 | ) | (1,613,067 | ) | |||
Repayments of long-term debt | — | (15,000,000 | ) | ||||
Repayments of equipment line of credit | (1,200,033 | ) | (469,578 | ) | |||
Net cash provided by (used in) financing activities | 16,403,540 | (10,447,842 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents | — | (8,837 | ) | ||||
Net change in cash and cash equivalents | 6,840,149 | (6,480,796 | ) | ||||
Cash and cash equivalents—Beginning of period | 8,225,764 | 13,915,094 | |||||
Cash and cash equivalents—End of period | $ | 15,065,913 | $ | 7,434,298 | |||
Supplementary disclosure of cash flow activity: | |||||||
Cash paid for taxes | $ | 800 | $ | 800 | |||
Cash paid for interest | $ | 22,482 | $ | 650,331 | |||
Supplemental disclosure of non-cash investing and financing activities: | |||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock | $ | 18,180 | $ | 18,180 | |||
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance | $ | 2,769,533 | $ | — | |||
Common stock issued upon conversion of Series B Convertible Preferred Stock | $ | 886 | $ | — |
• | Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and |
• | Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms. |
• | Raising capital through public and private equity offerings; |
• | Introducing operation and business development initiatives to bring in new revenue streams; |
• | Reducing operating costs by identifying internal synergies; and |
• | Engaging in strategic partnerships. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||
Numerator: Net loss attributable to common shareholders | $ | (3,775,628 | ) | $ | (4,298,026 | ) | $ | (15,090,413 | ) | $ | (22,355,494 | ) | |||
Adjustment for gain from change in fair value of derivative financial instruments—warrants | — | — | — | — | |||||||||||
Net loss used for diluted loss per share | $ | (3,775,628 | ) | $ | (4,298,026 | ) | $ | (15,090,413 | ) | $ | (22,355,494 | ) | |||
Denominator for basic and diluted net loss per share: | |||||||||||||||
Weighted-average shares used to compute basic loss per share | 20,622,660 | 3,038,806 | 10,945,249 | 2,735,526 | |||||||||||
Adjustments to reflect assumed exercise of warrants | — | — | — | — | |||||||||||
Weighted-average shares used to compute diluted net loss per share | 20,622,660 | 3,038,806 | 10,945,249 | 2,735,526 | |||||||||||
Net loss per share attributable to common stockholders: | |||||||||||||||
Basic | $ | (0.18 | ) | $ | (1.41 | ) | $ | (1.38 | ) | $ | (8.17 | ) | |||
Diluted | $ | (0.18 | ) | $ | (1.41 | ) | $ | (1.38 | ) | $ | (8.17 | ) |
September 30, | |||||
2018 | 2017 | ||||
Options to purchase Common Stock | 500,246 | 354,753 | |||
Warrants to purchase Common Stock | 22,189,533 | 747,709 | |||
Restricted Stock Units | 214,872 | 106,442 | |||
Series A Convertible Preferred Stock | 5,261 | 5,261 | |||
22,909,912 | 1,214,165 |
Fair Value Measurements at September 30, 2018 | |||||||||||||||
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total | ||||||||||||
Assets: | |||||||||||||||
Money market fund (1) | $ | 14,974,256 | $ | — | $ | — | $ | 14,974,256 | |||||||
Total Assets | $ | 14,974,256 | $ | — | $ | — | $ | 14,974,256 | |||||||
Liabilities: | |||||||||||||||
Derivative financial instruments—warrants | $ | — | $ | — | $ | 70,347 | $ | 70,347 | |||||||
Total Liabilities | $ | — | $ | — | $ | 70,347 | $ | 70,347 |
Fair Value Measurements at December 31, 2017 | |||||||||||||||
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total | ||||||||||||
Assets: | |||||||||||||||
Money market fund (1) | $ | 8,309,964 | $ | — | $ | — | $ | 8,309,964 | |||||||
Total Assets | $ | 8,309,964 | $ | — | $ | — | $ | 8,309,964 | |||||||
Liabilities: | |||||||||||||||
Derivative financial instruments—warrants | $ | — | $ | — | $ | 649,387 | $ | 649,387 | |||||||
Total Liabilities | $ | — | $ | — | $ | 649,387 | $ | 649,387 |
Description | Balance at December 31, 2017 | Realized (gains) or losses | Balance at September 30, 2018 | |||||||||
Derivative financial instruments—warrants | $ | 649,387 | $ | (579,040 | ) | $ | 70,347 |
As of September 30, 2018 | As of December 31, 2017 | ||||||
Furniture and office equipment | $ | 1,072,156 | $ | 1,076,709 | |||
Leasehold improvements | 1,994,514 | 1,994,514 | |||||
Laboratory equipment | 912,940 | 1,426,581 | |||||
3,979,610 | 4,497,804 | ||||||
Less—accumulated depreciation and amortization | (2,352,005 | ) | (2,071,492 | ) | |||
Property and equipment, net | $ | 1,627,605 | $ | 2,426,312 |
Nine Months Ended September 30, | |||||
2018 | 2017 | ||||
Estimated fair value of Trovagene common stock | 0.77-4.20 | 8.76-15.12 | |||
Expected warrant term | 0.3-5.1 years | 1.3-5.5 years | |||
Risk-free interest rate | 1.76-2.92% | 1.27-1.95% | |||
Expected volatility | 47-131% | 86-109% | |||
Dividend yield | 0 | % | 0 | % |
Date | Description | Number of Warrants | Derivative Instrument Liability | ||||||
December 31, 2017 | Balance of derivative financial instruments—warrants liability | 467,584 | $ | 649,387 | |||||
Change in fair value of derivative financial instruments—warrants during the period recognized as a gain in the condensed consolidated statements of operations | — | (579,040 | ) | ||||||
September 30, 2018 | Balance of derivative financial instruments—warrants liability | 467,584 | $ | 70,347 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||
Included in research and development expense | $ | 130,300 | $ | 219,480 | $ | 637,821 | $ | 798,143 | |||||||
Included in cost of revenue | — | 15,633 | 30,488 | 56,998 | |||||||||||
Included in selling, general and administrative expense | 147,921 | 1,186,067 | 1,237,343 | 2,387,445 | |||||||||||
Benefit from restructuring | — | — | — | (125,222 | ) | ||||||||||
Total stock-based compensation expense | $ | 278,221 | $ | 1,421,180 | $ | 1,905,652 | $ | 3,117,364 |
Nine Months Ended September 30, | |||||
2018 | 2017 | ||||
Risk-free interest rate | 2.5 | % | 1.82 | % | |
Dividend yield | 0 | % | 0 | % | |
Expected volatility | 91 | % | 87 | % | |
Expected term | 5.2 years | 5.2 years |
Total Options | Weighted-Average Exercise Price Per Share | Intrinsic Value | ||||||||
Balance outstanding, December 31, 2017 | 374,251 | $ | 48.52 | $ | — | |||||
Granted | 316,744 | $ | 3.12 | |||||||
Canceled / Forfeited | (189,540 | ) | $ | 36.50 | ||||||
Expired | (1,209 | ) | $ | 36.00 | ||||||
Balance outstanding, September 30, 2018 | 500,246 | $ | 24.35 | $ | 3,370 | |||||
Exercisable at September 30, 2018 | 355,696 | $ | 30.21 | $ | 1,950 |
Number of Shares | Weighted-Average Grant Date Fair Value Per Share | Intrinsic Value | ||||||||
Non-vested RSUs outstanding, December 31, 2017 | 106,200 | $ | 17.22 | $ | 391,878 | |||||
Granted | 204,750 | $ | 0.77 | |||||||
Vested | (77,572 | ) | $ | 13.83 | $ | 268,151 | ||||
Forfeited | (18,506 | ) | $ | 24.60 | ||||||
Non-vested RSUs outstanding, September 30, 2018 | 214,872 | $ | 2.14 | $ | 175,121 |
Total Warrants (1) | Weighted-Average Exercise Price Per Share | Weighted-Average Remaining Contractual Term (1) | ||||||
Balance outstanding, December 31, 2017 | 1,936,641 | $ | 11.34 | 4.4 | ||||
Granted | 20,700,000 | $ | 1.10 | |||||
Exercised | (447,108 | ) | $ | 3.60 | ||||
Balance outstanding, September 30, 2018 | 22,189,533 | $ | 1.94 | 4.6 |
• | Complete Phase 1b dose escalation cohorts and identify the recommended Phase 2 dose (“RP2D”) for the Phase 2 continuation trial (dependent upon the number of dose escalation cohorts required to reach the maximum tolerated dose or RP2D of onvansertib). |
• | Provide topline preliminary safety and efficacy data on the combination of onvansertib + LDAC and the combination of onvansertib + decitabine in patients treated through the end of 2018. |
• | Present data from the AML trial at the 60th annual American Society of Hematology (“ASH”) conference in December 2018. |
• | Initiate the Phase 2 segment of the AML trial, which will enroll approximately 32 patients for continued evaluation of safety and preliminary efficacy of onvansertib in combination with either LDAC or decitabine (provided the RP2D has been determined in Phase 1b). |
• | Complete enrollment and evaluation of the 3 safety lead-in patients with onvansertib at 24 mg/m2 in combination with abiraterone acetate (Zytiga®) and prednisone. |
• | Provide topline preliminary safety and efficacy data of onvansertib in combination with abiraterone acetate (Zytiga®) and prednisone in patients treated. |
• | Present data from the mCRPC trial at the 2019 Genitourinary Cancers Symposium (“ASCO GU”) |
• | Announced New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by the United States Patent and Trademark Office. |
• | Announced Exclusive License Agreement with Massachusetts Institute of Technology (“MIT”) for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer. |
• | Announced Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial. |
• | Announced Predictive Clinical Biomarker Approach to Identify AML Patients Most Likely to Respond to Onvansertib. |
• | Announced European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe. |
• | Announced Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial. |
• | Received United States Adopted Name (“USAN”) Approval for “Onvansertib” as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075. |
• | Received Positive Opinion for Orphan Drug Designation in the European Union for Onvansertib (PCM-075), Our Investigational Cancer Drug. |
• | Announced Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of Onvansertib (PCM-075) in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML. |
• | Announced the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of Onvansertib (PCM-075) in Combination with Zytiga® in Patients with mCRPC. |
• | Announced Completion of First Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Combination with Decitabine in Ongoing Phase 1b/2 AML trial. |
• | Announced Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 AML trial of Onvansertib (PCM-075) in AML. |
• | Announced Presentation of Data at American Association for Cancer Research (“AACR”) Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with Onvansertib (PCM-075) and Low-Dose Cytarabine. |
• | Announced Presentation of data at AACR Meeting 2018 Showing Synergy of Onvansertib (PCM-075) in Combination with FLT3 Inhibitors in AML. |
• | Announced First Patient Successfully Completes Cycle 1 of Treatment with Onvansertib (PCM-075) in Combination with Low-Dose Cytarabinein AML Trial. |
• | Announced Presentation of Data Showing Synergy of Onvansertib (PCM-075) in Combination with Zytiga® (abiraterone acetate) in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium. |
Three Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Royalties | $ | 72,568 | $ | 58,779 | $ | 13,789 | |||||
Diagnostic services | 4,303 | 58,119 | (53,816 | ) | |||||||
Clinical research services | 11,490 | 6,431 | 5,059 | ||||||||
Total revenues | $ | 88,361 | $ | 123,329 | $ | (34,968 | ) |
Three Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Salaries and staff costs | $ | 354,643 | $ | 301,919 | $ | 52,724 | |||||
Stock-based compensation | 130,300 | 219,480 | (89,180 | ) | |||||||
Outside services, consultants and lab supplies | 1,023,201 | 604,140 | 419,061 | ||||||||
Facilities | 270,032 | 254,681 | 15,351 | ||||||||
Travel and scientific conferences | 32,242 | 28,000 | 4,242 | ||||||||
Fees, license and other | 20,023 | 6,486 | 13,537 | ||||||||
Total research and development | $ | 1,830,441 | $ | 1,414,706 | $ | 415,735 |
Three Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Salaries and staff costs | $ | 535,582 | $ | 1,327,743 | $ | (792,161 | ) | ||||
Board of Directors’ fees | 105,233 | 120,085 | (14,852 | ) | |||||||
Stock-based compensation | 147,921 | 1,186,067 | (1,038,146 | ) | |||||||
Outside services and consultants | 158,285 | 318,378 | (160,093 | ) | |||||||
Legal and accounting fees | 230,690 | 609,149 | (378,459 | ) | |||||||
Facilities and insurance | 249,209 | 342,935 | (93,726 | ) | |||||||
Travel and conferences | 164,136 | 45,256 | 118,880 | ||||||||
Fees, license and other | 74,144 | 129,901 | (55,757 | ) | |||||||
Total selling, general and administrative | $ | 1,665,200 | $ | 4,079,514 | $ | (2,414,314 | ) |
Three Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Net loss attributable to common shareholders | $ | (3,775,628 | ) | $ | (4,298,026 | ) | $ | (522,398 | ) | ||
Net loss per common share — basic | $ | (0.18 | ) | $ | (1.41 | ) | $ | (1.23 | ) | ||
Net loss per common share — diluted | $ | (0.18 | ) | $ | (1.41 | ) | $ | (1.23 | ) | ||
Weighted average shares outstanding — basic | 20,622,660 | 3,038,806 | 17,583,854 | ||||||||
Weighted average shares outstanding — diluted | 20,622,660 | 3,038,806 | 17,583,854 |
Nine Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Royalties | $ | 174,046 | $ | 169,415 | $ | 4,631 | |||||
Diagnostic services | 83,650 | 142,482 | (58,832 | ) | |||||||
Clinical research services | 42,614 | 8,481 | 34,133 | ||||||||
Total revenues | $ | 300,310 | $ | 320,378 | $ | (20,068 | ) |
Nine Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Salaries and staff costs | $ | 1,270,042 | $ | 1,468,491 | $ | (198,449 | ) | ||||
Stock-based compensation | 637,821 | 798,143 | (160,322 | ) | |||||||
Outside services, consultants and lab supplies | 2,988,198 | 1,456,504 | 1,531,694 | ||||||||
Facilities | 644,750 | 842,196 | (197,446 | ) | |||||||
Travel and scientific conferences | 91,670 | 72,901 | 18,769 | ||||||||
Fees, licenses and other | 34,565 | 2,038,016 | (2,003,451 | ) | |||||||
Total research and development | $ | 5,667,046 | $ | 6,676,251 | $ | (1,009,205 | ) |
Nine Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Salaries and staff costs | $ | 2,335,228 | $ | 3,504,507 | $ | (1,169,279 | ) | ||||
Board of Directors’ fees | 355,177 | 347,205 | 7,972 | ||||||||
Stock-based compensation | 1,237,343 | 2,387,445 | (1,150,102 | ) | |||||||
Outside services and consultants | 625,890 | 925,808 | (299,918 | ) | |||||||
Legal and accounting fees | 518,743 | 3,395,070 | (2,876,327 | ) | |||||||
Facilities and insurance | 780,237 | 963,265 | (183,028 | ) | |||||||
Travel and conferences | 264,634 | 510,205 | (245,571 | ) | |||||||
Fees, license and other | 203,796 | 324,785 | (120,989 | ) | |||||||
Total selling, general and administrative | $ | 6,321,048 | $ | 12,358,290 | $ | (6,037,242 | ) |
Nine Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Net loss attributable to common shareholders | $ | (15,090,413 | ) | $ | (22,355,494 | ) | $ | (7,265,081 | ) | ||
Net loss per common share — basic | $ | (1.38 | ) | $ | (8.17 | ) | $ | (6.79 | ) | ||
Net loss per common share — diluted | $ | (1.38 | ) | $ | (8.17 | ) | $ | (6.79 | ) | ||
Weighted average shares outstanding — basic | 10,945,249 | 2,735,526 | 8,209,723 | ||||||||
Weighted average shares outstanding — diluted | 10,945,249 | 2,735,526 | 8,209,723 |
Nine Months Ended September 30, | |||||||||||
2018 | 2017 | Increase (Decrease) | |||||||||
Net loss attributable to common shareholders | $ | (15,090,413 | ) | $ | (22,355,494 | ) | $ | (7,265,081 | ) | ||
Adjustment for preferred stock dividend recognized from beneficial conversion features of Series B Convertible Preferred Stock issuance | 2,769,533 | — | 2,769,533 | ||||||||
Total adjusted net loss attributable to common shareholders | $ | (12,320,880 | ) | $ | (22,355,494 | ) | $ | (4,495,548 | ) | ||
Adjusted net loss per common share — basic and diluted | $ | (1.13 | ) | $ | (8.17 | ) | $ | (7.04 | ) | ||
Weighted average shares outstanding — basic and diluted | 10,945,249 | 2,735,526 | 8,209,723 | ||||||||
Adjustment for Series B Convertible Preferred Stock | — | — | — | ||||||||
Total adjusted weighted average shares outstanding — basic and diluted | 10,945,249 | 2,735,526 | 8,209,723 |
Exhibit Number | Description of Exhibit | |
101.INS | XBRL Instance Document | |
101.SCH | XBRL Taxonomy Extension Schema | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase | |
101.LAB | XBRL Taxonomy Extension Labels Linkbase | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase |
TROVAGENE, INC. | ||
November 7, 2018 | By: | /s/ Thomas Adams |
Thomas Adams | ||
Interim Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) |
1. | I have reviewed this quarterly report on Form 10-Q of Trovagene, Inc. (the “Registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions); |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
November 7, 2018 | /s/ Thomas Adams |
Thomas Adams | |
Interim Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) |
November 7, 2018 | /s/ Thomas Adams |
Thomas Adams | |
Interim Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) |
Document and Entity Information - shares |
9 Months Ended | |
---|---|---|
Sep. 30, 2018 |
Oct. 31, 2018 |
|
Document and Entity Information | ||
Entity Registrant Name | Trovagene, Inc. | |
Entity Central Index Key | 0001213037 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2018 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 22,990,942 | |
Document Fiscal Year Focus | 2018 | |
Document Fiscal Period Focus | Q3 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) |
Sep. 30, 2018 |
Dec. 31, 2017 |
---|---|---|
Preferred stock, par value (in USD per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 |
Common stock, par value (in USD per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 150,000,000 | 150,000,000 |
Common stock, shares issued (in shares) | 22,957,192 | 4,399,299 |
Common stock, shares outstanding (in shares) | 22,957,192 | 4,399,299 |
Series A Convertible Preferred Stock | ||
Preferred stock, shares authorized (in shares) | 277,100 | 277,100 |
Preferred stock, shares outstanding (in shares) | 60,600 | 60,600 |
Series A Convertible Preferred Stock, liquidation preference (in dollars) | $ 606,000 | $ 606,000 |
Series B Convertible Preferred Stock | ||
Preferred stock, shares authorized (in shares) | 8,860 | 8,860 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Income Statement [Abstract] | ||||
Royalties | $ 72,568 | $ 58,779 | $ 174,046 | $ 169,415 |
Diagnostic services | 4,303 | 58,119 | 83,650 | 142,482 |
Clinical research services | 11,490 | 6,431 | 42,614 | 8,481 |
Total revenues | 88,361 | 123,329 | 300,310 | 320,378 |
Costs and expenses: | ||||
Cost of revenues | 26,677 | 473,202 | 597,457 | 1,427,831 |
Research and development | 1,830,441 | 1,414,706 | 5,667,046 | 6,676,251 |
Selling, general and administrative | 1,665,200 | 4,079,514 | 6,321,048 | 12,358,290 |
Restructuring charges (benefit) | 421,351 | (46,472) | 664,686 | 1,669,526 |
Total operating expenses | 3,943,669 | 5,920,950 | 13,250,237 | 22,131,898 |
Loss from operations | (3,855,308) | (5,797,621) | (12,949,927) | (21,811,520) |
Interest income | 85,938 | 20,650 | 143,911 | 132,515 |
Interest expense | (16) | (37,123) | (25,177) | (1,010,256) |
(Loss) gain from change in fair value of derivative financial instruments—warrants | (2,500) | 1,528,669 | 579,040 | 2,012,747 |
Gain (loss) on extinguishment of debt | 0 | 0 | 17,974 | (1,655,825) |
Other income (loss), net | 2,318 | (6,541) | (68,521) | (4,975) |
Net loss | (3,769,568) | (4,291,966) | (12,302,700) | (22,337,314) |
Preferred stock dividend payable on Series A Convertible Preferred Stock | (6,060) | (6,060) | (18,180) | (18,180) |
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance | 0 | 0 | 2,769,533 | 0 |
Net loss attributable to common stockholders | $ (3,775,628) | $ (4,298,026) | $ (15,090,413) | $ (22,355,494) |
Net loss per common share - basic (in USD per share) | $ (0.18) | $ (1.41) | $ (1.38) | $ (8.17) |
Net loss per common share - diluted (in USD per share) | $ (0.18) | $ (1.41) | $ (1.38) | $ (8.17) |
Weighted-average shares outstanding — basic (in shares) | 20,622,660 | 3,038,806 | 10,945,249 | 2,735,526 |
Weighted-average shares outstanding — diluted (in shares) | 20,622,660 | 3,038,806 | 10,945,249 | 2,735,526 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statement - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Statement of Comprehensive Income [Abstract] | ||||
Net loss | $ (3,769,568) | $ (4,291,966) | $ (12,302,700) | $ (22,337,314) |
Other comprehensive income (loss): | ||||
Foreign currency translation loss | 0 | (1,544) | 0 | (13,486) |
Unrealized gain or reversal of previous losses on securities available-for-sale | 0 | 0 | 0 | 9,065 |
Total other comprehensive loss | 0 | (1,544) | 0 | (4,421) |
Total comprehensive loss | (3,769,568) | (4,293,510) | (12,302,700) | (22,341,735) |
Preferred stock dividend payable on Series A Convertible Preferred Stock | 6,060 | 6,060 | 18,180 | 18,180 |
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance | 0 | 0 | 2,769,533 | 0 |
Comprehensive loss attributable to common stockholders | $ (3,775,628) | $ (4,299,570) | $ (15,090,413) | $ (22,359,915) |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) |
9 Months Ended | |
---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Common stock and warrants | ||
Payments of stock issuance costs | $ (1,336,123) | $ (575,516) |
Series B Convertible Preferred Stock | ||
Payments of stock issuance costs | $ (497,617) |
Organization and Basis of Presentation |
9 Months Ended | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||
Organization and Basis of Presentation | Organization and Basis of Presentation Business Organization and Overview Trovagene, Inc. (“Trovagene” or the “Company”) headquartered in San Diego, California, is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene’s intellectual property and proprietary technology enables the Company to analyze circulating tumor DNA (“ctDNA”) and clinically actionable markers. Unique to the Company’s clinical development plan, and a key component of its precision cancer medicine approach, is the integration of predictive clinical biomarkers to identify patients most likely to respond to treatment. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of Trovagene, which include all accounts of its wholly owned subsidiary, Trovagene, Srl (dissolved in October 2017), have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December 31, 2017 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2017 included in the Company’s annual report on Form 10-K filed with the SEC on February 26, 2018. The Company made a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 12, effective June 1, 2018. All share and per share information in the unaudited condensed consolidated financial statements and the accompanying notes have been retroactively adjusted to reflect the reverse stock split for all periods presented. Liquidity Trovagene’s condensed consolidated financial statements as of September 30, 2018 have been prepared under the assumption that Trovagene will continue as a going concern, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. The Company has incurred net losses since its inception and has negative operating cash flows. Considering the Company’s current cash resources, including the net proceeds received from the offering of its equity securities in June 2018, management believes the Company’s existing resources will be sufficient to fund the Company’s planned operations through July 2019. On April 6, 2018, the Company paid off the outstanding Loan and Security Agreement (“Equipment Line of Credit”) entered in November 2015 to Silicon Valley Bank (“SVB”). Based on its current business plan and assumptions, the Company expects to continue to incur significant losses and require significant additional capital to further advance its clinical trial programs and support its other operations. The Company has based its cash sufficiency estimates on its current business plan and its assumptions that may prove to be wrong. The Company could utilize its available capital resources sooner than it currently expects, and it could need additional funding to sustain its operations even sooner than currently anticipated. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates, all of which would have a material adverse impact on the Company’s operations. The Company may also be required to:
The Company is evaluating the following options to raise additional capital, increase revenue, as well as reduce costs, in an effort to strengthen its liquidity position:
As of October 31, 2018, the Company has received approximately $1.6 million upon exercise of 5,681,667 warrants in connection with the December 2017 public offering. The Company continually assesses its spending plans to effectively and efficiently address its liquidity needs. NASDAQ Notice On September 5, 2017, the Company received a written notice from the NASDAQ Stock Market LLC (“NASDAQ”) that it was not in compliance with NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market, as the minimum bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days. In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company had a period of 180 calendar days, or until March 5, 2018, to regain compliance with the minimum bid price requirement. On March 6, 2018, the NASDAQ Capital Market informed the Company that it is eligible for an additional 180 calendar day period until September 4, 2018 to regain compliance with the minimum $1.00 bid price per share requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period. On September 7, 2018, the Company received a letter from NASDAQ indicating that, based upon the Company’s continued non-compliance with the Minimum Bid Price Rule, the Company’s common stock would be subject to delisting unless the Company timely requests a hearing before a NASDAQ Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel on September 14, 2018, which request will stay any further action by NASDAQ at least pending the issuance of a decision following the hearing and the expiration of any additional extension that may be granted by the Panel. The Company is scheduled to attend the hearing before the Panel on November 8, 2018. The Company is considering all of its options to regain compliance; however, there can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to evidence compliance with the continued listing criteria within the period of time that the Panel may grant it to do so. |
Summary of Significant Accounting Policies |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies During the nine months ended September 30, 2018, there have been no changes to the Company’s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, except as described below. Revenue Recognition The Company recognizes revenue when control of its products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: •Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. •Minimum royalties are recognized as earned, and royalties are earned based on the licensee’s use. The Company estimates and records licensee’s sales based on historical usage rate and collectability. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. This revenue stream does not meet the criteria for contracts with a customer under ASC 606 because it is not probable that the Company will collect substantially all the consideration to which it will be entitled in exchange for the goods and services transferred, nor can it reliably determine the expected transaction price. Therefore, the Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements. As a result of disposition of the its Clinical Laboratory Improvement Amendments (“CLIA”) - certified laboratory, this revenue stream is declining and overall insignificant to the Company. Clinical Research Revenue Revenue from clinical research consists of revenue from the sale of urine and blood collection supplies and tests performed under agreements with our clinical research and business development partners. Revenue is recognized when supplies and/or test results are delivered, which is when control of the product is deemed to be transferred. Restructuring Restructuring costs are included in loss from operations in the consolidated statements of operations. The Company has accounted for these costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations. One-time termination benefits are recorded at the time they are communicated to the affected employees. In March 2017, the Company announced a restructuring plan which was completed as of December 31, 2017. In May 2018, the Company closed its CLIA laboratory operations. Costs associated with winding down the CLIA laboratory were recorded in the restructuring cost in the September 30, 2018 financial statements. See Note 9 to the consolidated financial statements for further information. Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The following table sets forth the computation of basic and diluted earnings per share:
The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:
Recently Adopted Accounting Pronouncement In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which amends the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU 2018-07, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt this ASU 2018-07 as of September 30, 2018 and the adoption did not have an impact on the Company’s consolidated financial statements. Recent Accounting Pronouncement Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 changes accounting for leases and requires lessees to recognize the assets and liabilities arising from most leases, including those classified as operating leases under previous accounting guidance, on the balance sheet and requires disclosure of key information about leasing arrangements to increase transparency and comparability among organizations. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard. In July 2018, ASU 2018-11, Leases: Targeted Improvements, was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The new guidance will be effective for the Company starting in the first quarter of fiscal year 2019. The new standards will impact the Company’s accounting for its equipment and office leases and the Company is currently evaluating the impact of the new standards on its consolidated financial statements and processes. |
Fair Value Measurements |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2018 and December 31, 2017:
(1) Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets. The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2018:
The change in the fair value of the “derivative financial instruments—warrants” is recorded as a gain or loss in the Company’s consolidated statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40 and ASC Topic 480-10. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. |
Property and Equipment |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment | Property and Equipment Property and equipment consist of the following:
|
Equipment Line of Credit |
9 Months Ended |
---|---|
Sep. 30, 2018 | |
Debt Disclosure [Abstract] | |
Equipment Line of Credit | Equipment Line of Credit In November 2015, the Company entered into a Loan and Security Agreement (“Equipment Line of Credit”) with SVB that provided for cash borrowings for equipment (“Equipment Advances”) of up to $2.0 million, secured by the equipment financed. Under the terms of the agreement, interest is equal to 1.25% above the Prime Rate. Interest only payments were due on borrowings through November 30, 2016, with both interest and principal payments commencing in December 2016. All unpaid principal and interest on each Equipment Advance will be due on November 1, 2019. The Company has an obligation to make a final payment equal to 7% of total amounts borrowed at the loan maturity date. The Company is also subject to certain affirmative and negative covenants under the Equipment Line of Credit. On June 20, 2017, the Company received a Notice of Event of Default (“Default Letter”) from SVB which stated that Events of Default had occurred and SVB will decide in its sole discretion whether or not to exercise rights and remedies. On April 6, 2018, the Company paid approximately $1,100,000 to SVB. This payment repaid the outstanding Equipment Line of Credit loan in full. The Company recorded $25,161 in interest expense related to the Equipment Line of Credit during the nine months ended September 30, 2018. |
Derivative Financial Instruments - Warrants |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Financial Instruments - Warrants | Derivative Financial Instruments — Warrants Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”) or ASC Topic 480-10, Distinguishing Liabilities from Equity (“ASC 480-10”), Trovagene determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities. In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s condensed consolidated statements of operations. The Company estimates the fair value of these warrants using the Black-Scholes option pricing model. The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:
Expected volatility is based on historical volatility of Trovagene’s common stock. The warrants have a transferability provision and based on guidance provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment (“SAB No. 107”), for instruments issued with such a provision, Trovagene used the remaining contractual term as the expected term of the warrants. The risk-free rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date. The following table sets forth the components of changes in the Company’s derivative financial instruments—warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.
|
Stockholders' Equity |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity | Stockholders’ Equity Common Stock During the nine months ended September 30, 2018, the Company issued a total of 18,557,893 shares of Common Stock. The Company received gross proceeds of approximately $18.0 million from the sale of 9,140,000 shares of its common stock, 20,700,000 warrants, and 8,860 shares of Series B Convertible Preferred Stock through an underwritten public offering in June 2018. 473,497 shares were issued upon exercise of warrants for a weighted-average price of $3.41. 77,572 shares were issued upon vesting of restricted stock units (“RSUs”) and 8,860,000 shares were issued upon conversion of 8,860 shares of Series B Convertible Preferred Stock. In addition, 6,824 shares were issued for share rounding as a result of the reverse stock split. Stock Options Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow:
The unrecognized compensation cost related to non-vested stock options outstanding at September 30, 2018 and 2017, net of expected forfeitures, was $499,861 and $3,271,046, respectively, which is expected to be recognized over a weighted-average remaining vesting period of 1.3 and 2.2 years, respectively. The weighted-average remaining contractual term of outstanding options as of September 30, 2018 was approximately 7.6 years. The total fair value of stock options vested during the nine months ended September 30, 2018 and 2017 was $1,515,946 and $3,378,243, respectively. The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
A summary of stock option activity and changes in stock options outstanding is presented below:
On May 30, 2018, the number of authorized shares in the Trovagene 2014 Equity Incentive Plan (“2014 EIP”) was increased from 791,667 to 1,458,334. As of September 30, 2018 there were 637,798 shares available for issuance under the 2014 EIP. Restricted Stock Units The weighted-average grant date fair value of the RSUs was $0.77 and $19.08 per share during the nine months ended September 30, 2018 and 2017, respectively. A summary of the RSU activity is presented below:
At September 30, 2018 and 2017, total unrecognized compensation cost related to non-vested RSUs were $263,695 and $1,011,494, which are expected to be recognized over a weighted-average period of 2.0 and 2.5 years, respectively. The total fair value of vested RSUs during the nine months ended September 30, 2018 and 2017 were $1,072,714 and $1,285,578, respectively. Warrants A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
(1) Excluded the pre-funded warrants to purchase 26,389 shares of common stock at a nominal exercise price of $0.12 per share. The pre-funded warrants were exercised in full during the nine months ended September 30, 2018. Series B Convertible Preferred Stock On June 12, 2018, the Company closed an underwritten public offering for total gross proceeds of $18.0 million. The total related offering costs were approximately $1.8 million. The securities offered by the Company consisted of (i) 9,140,000 shares of common stock, at an offering price of $1.00 per share, (ii) warrants to purchase an aggregate of 20,700,000 shares of common stock, including the over-allotment option for 2,700,000 option warrants, at an exercise price of $1.10 per share, and (iii) 8,860 shares of Series B Convertible Preferred Stock, with a stated value of $1,000, and convertible into an aggregate of 8,860,000 shares of common stock. The conversion feature of the Series B Convertible Preferred Stock at the time of issuance was determined to be beneficial on commitment date. Because the Series B Convertible Preferred Stock is perpetual with no stated maturity date, and the conversions may occur any time from inception, the Company immediately recorded a one-time, non-cash deemed dividend of $2.8 million related to the beneficial conversion feature arising from the issuance of Series B Convertible Preferred Stock. This one-time, non-cash deemed dividend increased the Company’s net loss attributable to common stockholders and net loss per share. The holders of Series B Convertible Preferred Stock are entitled to receive dividends on an as-if-converted-to-Common-Stock basis when, as and if such dividends are paid on shares of the Common Stock. Each share of Series B Convertible Preferred Stock shall entitle the holder to vote on an as-if-converted-to-Common-Stock basis (not exceeding the Beneficial Ownership Limitation). Upon any liquidation, dissolution or winding-up of the Company, the holders of Series B Convertible Preferred Stock are entitled to participate on an as-if-converted-to-Common Stock basis (without giving effect to the Beneficial Ownership Limitation) with holders of the Common Stock in any distribution of assets of the Company. Each share of Series B Convertible Preferred Stock is convertible at the option of the holder into that number of shares of Common Stock determined by dividing the stated value of $1,000 per share, by the conversion price of $1.00 per share. As of September 30, 2018, there were no shares of Series B Convertible Preferred Stock outstanding. |
Commitments and Contingencies |
9 Months Ended |
---|---|
Sep. 30, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Executive and Consulting Agreements The Company has longer-term contractual commitments with various consultants and employees. Certain employment agreements provide for severance payments. Lease Agreements The Company leases approximately 26,100 square feet of office and laboratory space at a monthly rental rate of approximately $73,000. The lease will expire on December 31, 2021. The Company currently subleases certain office space and records the rental receipt under the subleases as a reduction of its rent expense. Research and Development and Clinical Trial Agreements In March 2017, the Company entered into a license agreement with Nerviano Medical Sciences S.r.l. (“Nerviano”) which granted the Company development and commercialization rights to NMS-1286937, which Trovagene refers to as onvansertib. Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK 1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs. Under the agreement, the Company is committed to pay $1.0 million for services provided by Nerviano, such as the costs to manufacture drug product, no later than June 30, 2019. As of September 30, 2018, approximately $368,000 has been paid for services provided. Terms of the agreement also provide for the Company to pay royalties based on certain development and sales milestones. The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material. Litigation Trovagene does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company’s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company’s business or financial condition. |
Restructuring Charges |
9 Months Ended |
---|---|
Sep. 30, 2018 | |
Restructuring and Related Activities [Abstract] | |
Restructuring Charges | Restructuring Charges In May 2018, the Company closed its CLIA laboratory operations in order to streamline the Company’s business model. The loss recognized from disposition of CLIA laboratory was reported as restructuring charges, a component of operating loss, in the condensed consolidated financial statements. During the nine months ended September 30, 2018, the Company recorded total restructuring charges of approximately $664,000 for CLIA laboratory disposal transactions, of which, approximately $187,000 was related to impairment loss on CLIA laboratory license, approximately $52,000 was related to loss on disposal of property and equipment and other non-capital assets, and approximately $425,000 was related to loss on sublease of office and laboratory space. In March 2017, the Company announced a strategic restructuring plan in connection with the expansion of precision medicine therapeutics to its business. The restructuring plan included a reduction in force and was completed in the last quarter of 2017. Restructuring charges of approximately $1.7 million were incurred and have been included as a component of operating loss for the nine months ended September 30, 2017. Of the total restructuring charges, approximately $1.2 million was related to termination of employees and an approximately $0.5 million charge related to impaired license fees. |
Subsequent Events |
9 Months Ended |
---|---|
Sep. 30, 2018 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Event Subsequent to the quarter end, the Company entered into an arrangement with Leucadia Life Sciences (“Leucadia”) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for AML. The cost of the services under the arrangement are expected to be up to $575,000. The Company’s Interim Chief Executive Officer (“CEO”), Dr. Thomas Adams, is a principal stockholder of Leucadia. In addition, in connection with the arrangement, the Company may enter into a consulting agreement with Tommy Adams, VP of Operations of Leucadia, who is the son of Dr. Adams. |
Summary of Significant Accounting Policies (Policies) |
9 Months Ended |
---|---|
Sep. 30, 2018 | |
Accounting Policies [Abstract] | |
Revenue Recognition | Revenue Recognition The Company recognizes revenue when control of its products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: •Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. •Minimum royalties are recognized as earned, and royalties are earned based on the licensee’s use. The Company estimates and records licensee’s sales based on historical usage rate and collectability. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. This revenue stream does not meet the criteria for contracts with a customer under ASC 606 because it is not probable that the Company will collect substantially all the consideration to which it will be entitled in exchange for the goods and services transferred, nor can it reliably determine the expected transaction price. Therefore, the Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements. As a result of disposition of the its Clinical Laboratory Improvement Amendments (“CLIA”) - certified laboratory, this revenue stream is declining and overall insignificant to the Company. Clinical Research Revenue Revenue from clinical research consists of revenue from the sale of urine and blood collection supplies and tests performed under agreements with our clinical research and business development partners. Revenue is recognized when supplies and/or test results are delivered, which is when control of the product is deemed to be transferred. |
Restructuring | Restructuring Restructuring costs are included in loss from operations in the consolidated statements of operations. The Company has accounted for these costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations. One-time termination benefits are recorded at the time they are communicated to the affected employees. In March 2017, the Company announced a restructuring plan which was completed as of December 31, 2017. In May 2018, the Company closed its CLIA laboratory operations. Costs associated with winding down the CLIA laboratory were recorded in the restructuring cost in the September 30, 2018 financial statements. See Note 9 to the consolidated financial statements for further information. |
Net Loss Per Share | Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. |
Recent Accounting Pronouncements | Recently Adopted Accounting Pronouncement In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which amends the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU 2018-07, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt this ASU 2018-07 as of September 30, 2018 and the adoption did not have an impact on the Company’s consolidated financial statements. Recent Accounting Pronouncement Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 changes accounting for leases and requires lessees to recognize the assets and liabilities arising from most leases, including those classified as operating leases under previous accounting guidance, on the balance sheet and requires disclosure of key information about leasing arrangements to increase transparency and comparability among organizations. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard. In July 2018, ASU 2018-11, Leases: Targeted Improvements, was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The new guidance will be effective for the Company starting in the first quarter of fiscal year 2019. The new standards will impact the Company’s accounting for its equipment and office leases and the Company is currently evaluating the impact of the new standards on its consolidated financial statements and processes. |
Summary of Significant Accounting Policies (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Computation of Basic and Diluted Earnings per Share | The following table sets forth the computation of basic and diluted earnings per share:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share | The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:
|
Fair Value Measurements (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of the Company’s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy | The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2018 and December 31, 2017:
(1) Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Changes in the Fair Value of the Company’s Level 3 Liabilities | The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2018:
|
Property and Equipment (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Components of Property and Equipment | Property and equipment consist of the following:
|
Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative financial instruments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assumptions Used to Determine the Fair Value of the Warrants | The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Components of Changes in the Company’s Derivative Financial Instruments Liability Balance | The following table sets forth the components of changes in the Company’s derivative financial instruments—warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.
|
Stockholders' Equity (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stock-Based Compensation Expense | Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards | The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Stock Option Activity and of Changes in Stock Options Outstanding | A summary of stock option activity and changes in stock options outstanding is presented below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity | A summary of the RSU activity is presented below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Warrant Activity and Changes in Warrants Outstanding | A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
(1) Excluded the pre-funded warrants to purchase 26,389 shares of common stock at a nominal exercise price of $0.12 per share. The pre-funded warrants were exercised in full during the nine months ended September 30, 2018. |
Organization and Basis of Presentation (Details) |
9 Months Ended | 10 Months Ended | |||
---|---|---|---|---|---|
Jun. 01, 2018 |
Sep. 30, 2018
USD ($)
$ / shares
shares
|
Sep. 30, 2017
USD ($)
|
Oct. 31, 2018
USD ($)
shares
|
Dec. 31, 2017
$ / shares
|
|
Subsequent Event [Line Items] | |||||
Common stock, par value (in USD per share) | $ / shares | $ 0.0001 | $ 0.0001 | |||
Proceeds from exercise of warrants | $ | $ 1,612,667 | $ 0 | |||
Warrant exercised (in shares) | shares | 447,108 | ||||
Subsequent Event | |||||
Subsequent Event [Line Items] | |||||
Proceeds from exercise of warrants | $ | $ 1,600,000 | ||||
Common Stock | |||||
Subsequent Event [Line Items] | |||||
Stock split, ratio | 0.0833 | ||||
Common Stock | Subsequent Event | |||||
Subsequent Event [Line Items] | |||||
Warrant exercised (in shares) | shares | 5,681,667 |
Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares |
9 Months Ended | |
---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Net Loss Per Share | ||
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares) | 22,909,912 | 1,214,165 |
Stock Option | ||
Net Loss Per Share | ||
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares) | 500,246 | 354,753 |
Warrants | ||
Net Loss Per Share | ||
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares) | 22,189,533 | 747,709 |
Restricted Stock Units (RSUs) | ||
Net Loss Per Share | ||
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares) | 214,872 | 106,442 |
Series A Preferred Stock | Convertible Preferred Stock | ||
Net Loss Per Share | ||
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares) | 5,261 | 5,261 |
Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details) - Warrants |
9 Months Ended |
---|---|
Sep. 30, 2018
USD ($)
| |
Reconciliation of the beginning and ending balances | |
Balance at December 31, 2017 | $ 649,387 |
Realized (gains) or losses | (579,040) |
Balance at September 30, 2018 | $ 70,347 |
Property and Equipment (Details) - USD ($) |
Sep. 30, 2018 |
Dec. 31, 2017 |
---|---|---|
Property, equipment and depreciation and amortization | ||
Property and equipment, gross | $ 3,979,610 | $ 4,497,804 |
Less—accumulated depreciation and amortization | (2,352,005) | (2,071,492) |
Property and equipment, net | 1,627,605 | 2,426,312 |
Furniture and office equipment | ||
Property, equipment and depreciation and amortization | ||
Property and equipment, gross | 1,072,156 | 1,076,709 |
Leasehold improvements | ||
Property, equipment and depreciation and amortization | ||
Property and equipment, gross | 1,994,514 | 1,994,514 |
Laboratory equipment | ||
Property, equipment and depreciation and amortization | ||
Property and equipment, gross | $ 912,940 | $ 1,426,581 |
Equipment Line of Credit (Details) - Line of Credit - USD ($) |
1 Months Ended | 9 Months Ended | |
---|---|---|---|
Apr. 06, 2018 |
Nov. 30, 2015 |
Sep. 30, 2018 |
|
Line of Credit Facility [Line Items] | |||
Line of credit borrowing capacity (up to) | $ 2,000,000 | ||
Final payment of total amounts borrowed, percentage | 7.00% | ||
Repayments of debt | $ 1,100,000 | ||
Interest expenses recorded | $ 25,161 | ||
Prime Rate | |||
Line of Credit Facility [Line Items] | |||
Interest above base rate | 1.25% |
Stockholders' Equity - Warrants (Details) - $ / shares |
9 Months Ended | 12 Months Ended |
---|---|---|
Sep. 30, 2018 |
Dec. 31, 2017 |
|
Number of Warrants | ||
Balance of warrants outstanding at the beginning of the period (in shares) | 1,936,641 | |
Granted (in shares) | 20,700,000 | |
Exercised (in shares) | (447,108) | |
Balance of warrants outstanding at the end of the period (in shares) | 22,189,533 | 1,936,641 |
Weighted Average Exercise Price Per Share | ||
Weighted average exercise price of warrants at the beginning of the period (in USD per share) | $ 11.34 | |
Granted (in USD per share) | 1.10 | |
Exercised (in USD per share) | 3.60 | |
Weighted average exercise price of warrants at the end of the period (in USD per share) | $ 1.94 | $ 11.34 |
Term | ||
Weighted-Average Remaining Contractual Term | 4 years 7 months 13 days | 4 years 4 months 21 days |
Pre-funded Warrant [Member] | Public Offering [Member] | ||
Number of Warrants | ||
Exercised (in shares) | (26,389) | |
Term | ||
Exercise price of warrants (in USD per share) | $ 0.12 |
Commitments and Contingencies (Details) $ in Thousands |
9 Months Ended |
---|---|
Sep. 30, 2018
USD ($)
ft²
| |
Commitments and Contingencies Disclosure [Abstract] | |
Area under lease (in square feet) | ft² | 26,100 |
Monthly rental rate | $ | $ 73 |
Commitments and Contingencies - Research and Development Agreements (Details) - Nerviano - USD ($) $ in Thousands |
1 Months Ended | 9 Months Ended |
---|---|---|
Mar. 31, 2017 |
Sep. 30, 2018 |
|
Other Commitments [Line Items] | ||
Other commitment | $ 1,000 | |
Research and Development Arrangement | Research and Development Expense | ||
Other Commitments [Line Items] | ||
Research and development expense | $ 368 | |
Licensing Agreements | ||
Other Commitments [Line Items] | ||
Research and development expense | $ 2,000 |
Restructuring Charges (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges (benefit) | $ 421,351 | $ (46,472) | $ 664,686 | $ 1,669,526 |
Gain (loss) on disposal | 52,000 | |||
Employee Severance | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges (benefit) | 1,200,000 | |||
Impaired Long-Lived Assets | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges (benefit) | 187,000 | $ 500,000 | ||
Sublease | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges (benefit) | $ 425,000 |
Subsequent Events (Details) $ in Thousands |
Oct. 18, 2018
USD ($)
|
---|---|
Subsequent Event | |
Subsequent Event [Line Items] | |
Related party committed expenditures | $ 575 |
D@IKWTC^:X1M,]7RB9"K^'BX@,3PHP1RE
MD2ZNI.R=-VIB02F*/X^[T'$?QIMT/\'6 =YZTGR
M^*F&PO
M=V]R:W-H965T
Z3"?&HW1:
M3-J+0Q(2)$DZ6J1+'(93B<%48B"5D>5%BXE[(:(H)?C*"B1@G 2($\ "*2B0
M?GX/9*! ]O&D/V; I&/S@P--P4#3BT DOB) ,'S(\>?-DBMU@@!VPW&A<-6$
M#'=S%H978L''DP1 K.B*!'Q 2?@?CN%#1:!31<;E*KK8RW&2D?ZQ:F.A7D$V
M'^T?5.R+6GIKKG1MMQ5XQ[EB6A1/M-Q!WQ.Z3LEVRC13W1;MQ[+M*-ZXBP#J
M;B/Y/U!+ P04 " #+@&=- )>+! <# P# &0 'AL+W=O\@C^DUUY_5[1_9%\1]KZ_^DWR1N8$WF9AG[%5>MT=O?ZVU*GH6DTJ1
M_NK.6=F>;]T=$?5A> #I \@08)[]5@#M ^AK 'LS@/4!; @@;P?P/H"_!K0I
M!5WMK9C;5*>K1:5N7M7MATO:;#MXX&:Y]LUDNSKM/:-G;69?5I3Q1?#2$/68
M=8B=6A!,PE("U!.R.0%AJ=QC18LJN#!$3 I8@+@P8 8A#2Q4$EX0\XK8V+HX"
M"#I:Z;OZ.%H?1^J+K80Z#!\GQ($G(R&[A%P
RW
MX!@^:5JXF/ Y]N%:C&B2!]\[;;SQE*O1[]!/KG[RWG^X^(\.IGRAZ7J XK93
MS3S9_+7,1 F43?L\>#0[MUW'/F$^_8ULO1%RK"P[?/G@P\YG2OM*'D
M< "L=9&I#^9JGN_(X4UW05>FS;7I]_3#N0F8/R:?*0MS
MYG;[;-BJ(2#Y:XD6B!6#HGDH$-I6[*JZW\ L45>A,NJ6T!BJOM0HER4AK[E5
MV#62G
!8P(R8D2_'3?1>* PS4;.
M$27C6VQ'VVN Y)"MZHY)D"Z?@^6%DL $F>(\;2A,V7EBS#^08RMYN?#IV9T(
M ^_"FP #LQ0:J[\_4!*?1F&RZ.#UD.CG@@-.\*[04+D]%F:34ERUTI_I0SPJ
M3"@C?L6)QVG,Y1"E(=#]E@/]B4\1H+3/3L*861G'F&4T<_>HE%//NL:&NM3
M%0O:_/Q6)8S(N4LCF;I+JY5,T=&C=[>,XV9
V[E8MXL("B^,T*JENE#=C%4?N
M9PBDZ)(>ZS1BM\NMDQPJ96"7K> XHGJV-*.<>J>O:9@D'%7TRJK2:HIKI%SR
M-3^.;H[E7@!'+=)CMI4?\SB<%X,%)*A4/@5WW;#OKUJG@[M;)=:]$7A8=O
5VJ=3S49LF2!-QKDYL,1G9*K.S7&YKT7/^]::GWYZ5&V2FRX=VK!7
MV3!><$RDO(6SPB9 G&HO=^C0WID\6&NOGRB7#7Z@JK*$W;7^>15(/.GXN7JM
M?BR4T[2RMQ""Z#D%VAAUV^T :BMY0^X<-_NP^)3P\
M9K=,52 1-5<1G/
T>1>_ K&OA
MW1H(_>"@"LEOLE8KF*4X3X<-M@OGSQ>^"Q@ #VI1/!%.2HDY0Y
MQEUX?S*O_ :8 @RN0'7,.P62[VXZB,$*!DA?- ,5[?D16U@X7V 9>)$=I Y@YDZ0BAR@J9+)@$&L[7XNMB5DN":(D'8_LQ
MP@I0^B[9_&DSMN,M[UV@F;]IGWOK#2]H"\# 3PD=#-LFQJM$YZQB)";D ,)E
M>2@BZBN3:NPLK)K,+C$AK:4,'NU>*SBG..?,FI;F=>Z3^'$$T\RL;]S'% O7Y*[,0W[,/=3#
M3B! 3;<65A< 6327QIN_"O2YB+WWX>XI8]]/Q<\@S%;7.QZ:0[/S?MU7$\
MJ4[K*E8.>N;0N>:RWU+YT"RJ(1MBN]625_9#^,U7B\NT)G02'-@;.WB $[XB
M;ZO_'I9I_?=#:$_ MAJLVR>H.V\[IV7H?IDZ4/,_HJX'V^',PETN^OGZ/?R^
M?CS)/,'V^>JMX]Q!7F3Z(M,O*V6WAV%?F[)[(:*Z5ZKM;*U
+Z4I,O^?9.3=(LN8
MKWY='-$SL!*IH?'M>-'NL)%,[1MQJ_[J!/1VA1=*>.)=#-$)+ B5UI=U.%)
MJ-!6_H\)*J/J Z.]/3EGN_UPUX75,6F]=%.->?0205#K L518V%=26D&BKGV
M>E*\>3"O)Z3+ S,2AJEX,1OXO"]W\=VV%<7;JW
.JII-Q'7$PO \N.Q5+'2$D'
MI=;[.(>D0J?I"QY8ED8/"Y12*9Z$&$NXB<+VB27YA&
>\OQ6)>9-IV>49M\(3^N.%@RI>L ?TM^!J$4L2]^#X9MF@#@I-R.L@,R<2=J2P'>!N %
M^AY\ IO)#T/L&R,O#/B_8G13N8.2R"S;#C!T!K?,LB!XFTT#?\DB9\D1+?#_
M-TV0)<#W'?BC2S0G'WSW09CF&:RXUF,8.TFL30X8QF9SCAM V8"=D*?@ 8ZM
MXZ&\VGX;!>7#ZZ0:;]9DG<(EHXZ&BO
M_ #L%%6
M-F4^GR.-_,,%[]()X,+G*3&8URUZ"3R-@/ENS6E[*YN[,F#S#<+0AP$ UO\=
MV'+RTXF^!G ?<*[E#M"S$9S^-0!7/ IBM N1D;Z!.V&OC]BHF2I]?3K41^-)
MKS,9#OMCU1PDU=0G2F?4K(V:O0&*G"KUP-I*XPY&R-)5#18A [V]
S&2-
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M=AQX8 OBTH'AY^ZC@0S\(.1X]TF0)_7UY+X]F_DV\2.7,;OA0:H/-\)@RQNNV5@6YS)D
MB&= ],&,%4D_LU79QY7=ZW/J#7<5=[?I=\&+O4W2W*WWK@CS(/28\(T4>ZHO
M
"?OHX(SSAZQ5___(V52=CSF?O+L&=UW 4)@O/
MYBN\T ?5OH*Y_S2 6.S7?_[CE_D=I=)Z%S ^R1UX/N)\#NCSF[#IZ#U\$Z-_
MO?IXCJ#PW_:?5^>OF!S"%]#QD[-NK^MX7OO,.S\[=3Y^['KV1^?#A>>>.^ZI
M?7;ZZM=[[DEY2)XXN;TN456IR[AZRK,DJ9*FLTQJA^(@5NMU;[P=O$$2JY0
MXSR-"W0Q FX0*F,X'B83@.,0N2]6HUA#4^XR:NJIE\.$"=J "&GD)>"A=+N>
MU1^L;J;?RL77R0[M'945M<66D@3@H N868=L'&M2$,1J,=1WZ83PE^KX#9
MP4B;7CO]ELW@L@ <"3.]U!X.CH[B@3 V%@/+Z=@6S,6FAR*;-A=U8'?W0[,%
M5-OR;(,-OLV/OUAZ!C?RS+[5[QD79[;MC)T^MML,M"..TC$FYK((\3;&;%G(
M9NDU8#D\!J[.G27P'L5W9
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M%HLIER%J=U%!;%%R-_-M.=@>5TUF_(,SC+67J:"Q=#9'A^
M
^]8J%(6(#^)D^26%ZG698,^E%6\4D4
M@.>J].C/;U@$H?N.?AH8,B!D%%+=<-0SEM$PD4F0:1H8CY W8C[:J!$:1]6)
M')WD""N&)TET *<
M%XA3@1&)W@LM"J+$(*+OGQ2/ZM$F#V:Y.+.>@F$6< &DA]D7S*0!>F)#L=)[
M*:5P'D5N+!(%EDA;1A )0:L( U$1]7B&T&?&D(FARD6,#VVX,)5?+X< Q8^7
M9Z$=.H\,*%U2JGDH#$720MLY"QYY3!VR/DIF530P+AY/$_;,:#(/8OG8LMI3
M^+ PJV" ZXT%X/I&FCQ